GSK Receives FDA Approval for Priorix, a Measles, Mumps, and Rubella (MMR) Vaccine, Marking U.S. Market Debut

SmartCom APP learned that British pharmaceutical manufacturer GSK (GSK.US) announced on Monday that the U.S. Food and Drug Administration (FDA) has approved its measles, mumps, and rubella (MMR) combined vaccine Priorix.

GSK said that this approval has enabled Priorix to be launched in the U.S. for the first time. The vaccine has been licensed in more than 100 countries, including all European nations.

GSK Senior Vice President Judy Stewart stated: "Measles, mumps, and rubella are acute, highly contagious viral diseases that cause significant morbidity and mortality worldwide. In recent years, measles outbreaks have occurred in the United States and other countries, with more than 400,000 confirmed cases in 2019."